Improved Detection of Minimal Residual Disease in AML: Validation of IDH1/2 ddPCR Assays in the Perspective of Treatment with Target Inhibitors
Authors:
- Katsiaryna NikitsenkaKNKatsiaryna Nikitsenka
- Giacomo DanieliGDGiacomo Danieli
- Lucia TombolanLTLucia Tombolan
- Barbara ManciniBMBarbara Mancini
- Davide FacchinelliDFDavide Facchinelli
- Giorgia ScottonGSGiorgia Scotton
- Alberto TosettoATAlberto Tosetto
- Omar PerbelliniOPOmar Perbellini
- Daniela ZuccarelloDaniela Zuccarello
- Elisabetta NovellaENElisabetta Novella
Open Access
- 26 October 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10397
Abstract
Mutations in IDH1/2 are frequent in Acute Myeloid Leukemia (AML), defining a molecularly distinct subgroup with therapeutic implications due to the availability of specific inhibitors. Accurate monitoring of treatment response is crucial and Droplet Digital PCR (ddPCR) offers a sensitive approach for quantifying mutational burden in IDH-mutated AML. This study aimed to optimize and validate ddPCR assays specific for IDH1 R132 and IDH2 R172/R140 mutations for future use in Minimal Residual Disease (MRD) monitoring. Four ddPCR assays were set to evaluate the trend of IDH1/2 mutations in 191 diagnostic and follow-up samples. Each validation procedure included determining the limit of blank (LOB) and limit of detection (LOD) using titration series. Moreover, in AML harboring both IDH and NPM1 mutations, we performed generalized estimating equations (GEE) to assess the association between IDH fractional abundance and NPM1 RQ-Ratio across time points. Four IDH1/2 ddPCR assays were validated, demonstrating high sensitivity with limits of detection of 0.07% for IDH1 R132H, 0.1% for IDH2 R140Q and R172K, and 0.2% for IDH1 R132C. The method also exhibited excellent intra-run reproducibility, providing consistent results for patient follow-up. Comparison of IDH and NPM1 trends during follow-up revealed a statistically significant positive correlation, both in raw (β = 0.079, p = 0.001) and ranked data (β = 0.99, p = 0.004), suggesting a co-dynamic pattern potentially useful for surrogate monitoring. While our study cannot yet define the clinical role of IDH mutation assessment by ddPCR due to the lack of comparative follow-up studies, it establishes a solid methodological foundation for standardizing minimal residual disease evaluation via ddPCR, paving the way for future prospective validation.Keywords
This publication has 24 references indexed in Scilit:
- Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panelAmerican Journal of Hematology, 2023
- Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trialsLeukemia Research, 2023
- Evaluation of two new highly multiplexed PCR assays as an alternative to next‐generation sequencing for IDH1/2 mutation detectionMolecular Oncology, 2022
- Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid LeukemiaNew England Journal of Medicine, 2022
- IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?Clinical Biochemistry, 2018
- Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLNew England Journal of Medicine, 2018
- Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-AnalysisClinical Cancer Research, 2017
- Isocitrate dehydrogenase mutations in myeloid malignanciesLeukemia, 2016
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- Characteristics, clinical outcome, and prognostic significance of IDH mutations in AMLAmerican Journal of Hematology, 2015